NCT02449070

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction : A Randomized Clinical Trial

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 86 (estimated)
• Sponsor: Pusan National University Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether nicorandil reduce cardiac infarct size in patient with ST-segment elevation acute myocardial infarction.

Detailed description

Study objective : To investiage whether nicorandil treatment reduce infarct size measured by cardiac MRI at 6 months after primary PCI Allocation : 1. Nicorandil arm : Recieve nicorandil 4 mg i.v. before undergoing PCI, additionall 2mg i.c. just before 1st ballooning, additionall 2mg i.c. just before stenting, After successful PCI, 10 mg/day (or 5 mg/day) p.o. for 6 months. 2. Control arm : Recieve standard treatment including PCI, but avoid nicoranil and adenosine. Follow-up and Measurement : Cardiac MRI scans are scheduled at 5 days and 6 months after primary PCI. Clinically followed upto 6 months after parimary PCI.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Nicorandil	4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting

Timeline

• Start date: 2015-05-01
• Primary completion: 2018-10-01
• Completion: 2018-10-01
• First posted: 2015-05-20
• Last updated: 2017-09-20

Locations

1 site across 1 country: South Korea